Abstract
This article discusses rosacea, a common facial dermatosis of uncertain etiology and recent investigations that have begun to shed considerable light on the sequence of events leading to clinical manifestations of rosacea. The article content is based on a dedicated meeting about rosacea sanctioned by the American Acne & Rosacea Society (AARS) and represents the consensus of the authors and AARS Board of Directors.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Dermatologic Agents / therapeutic use
-
Dicarboxylic Acids / therapeutic use
-
Doxycycline / therapeutic use
-
Humans
-
Immunity, Innate / physiology
-
Inflammation / immunology
-
Inflammation / physiopathology
-
Low-Level Light Therapy
-
Metronidazole / therapeutic use
-
Rosacea / classification
-
Rosacea / immunology
-
Rosacea / physiopathology*
-
Rosacea / therapy*
-
Skin / blood supply
-
Skin / immunology
-
Skin / physiopathology
-
Telangiectasis / physiopathology
-
Th1 Cells / immunology
-
Toll-Like Receptor 2 / immunology
-
Vasodilation / immunology
-
Vasodilation / physiology
Substances
-
Dermatologic Agents
-
Dicarboxylic Acids
-
Toll-Like Receptor 2
-
Metronidazole
-
azelaic acid
-
Doxycycline